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Abstract
Background: Cooling may reduce infarct size and improve neurological outcomes in patients with ischaemic stroke.
In phase II trials, cooling awake patients with ischaemic stroke has been shown to be feasible and safe, but the effects
in functional outcomes has not yet been investigated in an adequately sized randomised clinical trial.
Methods/design: The EuroHYP-1 trial is a multinational, randomised, superiority phase III clinical trial with masked
outcome assessment testing the benefits and harms of therapeutic cooling in awake adult patients with acute ischaemic
stroke. The outcomes dealt with here include the primary outcome the Rankin score (mRS) at day 91 +/-14 days after
randomisation. The secondary and exploratory outcomes at day 91 +/-14 days unless otherwise stated encompassing: (1)
death or dependency, defined as mRS score > 2; (2) death; (3) National Institutes of Health Stroke Score; (4) brain infarct
size at 48 +/-24 hours; (5) EQ-5D-5 L score, and (6) WHODAS 2.0 score. Other outcomes are: the primary safety outcome
serious adverse events; and the incremental cost-effectiveness, and cost utility ratios. The analysis sets include (1) the
intention-to-treat population, and (2) the per protocol population. The sample size is estimated to 800 patients (5% type
1 and 20% type 2 errors). All analyses are adjusted for the protocol-specified stratification variables (nationality of centre),
and the minimisation variables. In the analysis, we use ordinal regression (the primary outcome), logistic regression (binary
outcomes), general linear model (continuous outcomes), and the Poisson or negative binomial model (rate outcomes).
Discussion: Major adjustments compared with the original statistical analysis plan encompass: (1) adjustment of analyses
by nationality; (2) power calculations for the secondary outcomes; (3) to address the multiplicity problem using of a
fixed-sequence testing procedure starting with the primary outcome followed by the secondary outcomes ordered
according to falling power; (4) assignment of worst possible score to patients who are not alive at the planned date of
measurement of the continuous scores; (5) improved imputations; (6) outline of a supplementary exploratory analysis of
the temperature measurements and time to death; and (7) substantial reduction of sample size.
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Introduction
The EuroHYP-1 trial is a multicentre, randomised, super-
iority phase III international clinical trial with masked out-
come assessment testing the benefits and harms of
therapeutic cooling in awake adult patients with acute
ischaemic stroke (website: http://www.eurohyp1.eu). The
trial is designed according to the SPIRIT guidelines, and the
background, design, and rationale have previously been
published [1]. The EuroHYP-1 trial protocol has been avail-
able online on www.ClinicalTrials.gov since the start of the
trial on 4 April 2013. The trial is endorsed and supported
by European Clinical Research Infrastructures Network
(ECRIN) (www.ecrin.org).
Here we describe the updated detailed statistical ana-
lysis plan that has been finalised while data collection in
the EuroHYP-1 trial is underway, and to which all data
analyses in the main publication of the EuroHYP-1 trial
results will adhere. A detailed statistical analysis plan
was part of the protocol, and the Steering Group of the
EuroHYP-1 trial unanimously approved the statistical
analysis plan on 30 March 2016. The present amend-
ments of the original statistical analysis plan focus on
the primary and the secondary outcomes. The amend-
ments have been made in order to make the analysis
more concrete and transparent. Patient recruitment of
800 patients is expected to be completed, and the final
follow-up is predicted to occur in 2018–19, after which
the database will be locked and data will be analysed.
Methods
Objective of the EuroHYP-1 trial
The primary aim of the EuroHYP-1 trial is to determine
whether systemic cooling to a target temperature of
34–35 °C, started within 6 hours of onset of stroke and
maintained for up to 12 hours thereafter, improves out-
comes in patients with acute ischaemic stroke. Inclu-
sion and exclusion criteria are described in the design
article in Tables 1 and 2 [1].
The null hypothesis is that there is no difference in
death and disability as defined by a score on the modified
Rankin Score (mRS) scale measured at 91 +/- 14 days after
randomisation of the patient.
For an overview of patient schedule and data collection
see Fig. 1.
The sample size
Originally, we planned to demonstrate or reject an
absolute difference of 7% between the intervention
groups (equivalent to an odds ratio (OR) of 0.74) and
allowing for 3% loss to follow up in a sample size of
1500 randomised patients with a type 1 error risk of
5% and a type 2 error risk of 10% (EuroHYP-1,
EudraCT number 2012-002944-25, version 2, 20 De-
cember 2012). Due to exceptionally slow enrolment,
we realised that this target was no longer realistic.
Accordingly, in 2014, the sample size was downgraded
to 800 patients based on considerations explained in
version 4 of the protocol (EuroHYP-1, EudraCT num-
ber 2012-002944-25, European Database on Medical
Devices (EUDAMED) number CIV-12-09-008821,
planned trial period July 2013 to March 2017
(45 months), version 4, date 29 June 2015). Currently,
the project has been prolonged until 31 July 2018.
Adjusting variables
The randomisation is stratified according to the nation-
ality of the participating centres and, within each
Table 1 Baseline characteristics of the participants in the EuroHYP-1 trial
Baseline characteristics Intention-to-treat population Per protocol population
Intervention group Control group Intervention group Control group
Centre
- name of centre 1, N (%)
- name of centre 2, N (%)
- name of centre 3, N (%)
- etc
Intention to perform thrombolysis, N (%)
Surface cooling, N (%)
Males, N (%)
Stroke severity (NIHSS), mean (SD), N
Age≤ 65 years, N (%)
Age, mean (SD), N
Visible ischaemic lesion on brain imaging, N (%)
Time since symptom onset, N≤ 4 hours (%)
NIHSS National Institutes of Health Stroke Score, SD standard deviation
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stratum, the patient allocation is based on probabilistic
minimisation (80:20) using the following factors:
 Intention to perform thrombolysis (yes compared to
no).
 Method of cooling (surface compared to
endovascular).
 Sex (male compared to female).
 Stroke severity (National Institutes of Health Stroke
Score (NIHSS)) 6–12 compared to 13 or higher).
 Age (≤ 65 years compared to > 65 years).
 Visibility of a relevant ischaemic lesion on the first
brain imaging (yes compared to no).
 Time since symptom onset (≤ 4 hours compared to
4–6 hours).
The primary analyses will be adjusted by the protocol-
specified stratification variable country and the seven
minimisation factors.
Flow of patients and baseline characteristics
The flow of patients will be reported according to the
CONSORT guidelines (Fig. 2). Patients’ baseline character-
istics will be reported in a table (Table 1) for the intention-
to-treat population and for the per protocol population.
Definition of the efficacy and safety outcomes
Outcomes in the original statistical analysis plan (SAP)
included in the EuroHYP-1 protocol are defined as pri-
mary, secondary, and exploratory. In the present SAP,
we deal only with the primary and secondary outcomes
as well as one safety outcome and one health-economic
outcome. For information on the exploratory outcomes
mentioned and defined in the EuroHYP-1 trial protocol
and the analyses of these outcomes the reader is there-
fore referred to the protocol [1].
The primary outcome
The primary outcome is degree of disability post stroke
as measured by the seven-level modified Rankin Scale
measured in the period 91 ± 14 days after the patient’s
randomisation.
The secondary outcomes originally selected
The order of secondary outcomes as originally selected
in the protocol was:
 Death or dependency, defined as a score on the
mRS > 2 at outcome assessment in the period day
91 ± 14 days after randomisation. Type: binary.
 Death at outcome assessment in the period day 91 ±
14 days after randomisation. Type: binary.
 Score on National Institute of Health Stroke Scale
(NIHSS) at outcome assessment in the period day
91 ± 14 days after randomisation. Type: continuous.
 EuroQoL quality-of-life (EQ-5D-5 L) score at outcome
assessment in the period day 91 ± 14 days after
randomisation. Type: continuous.
 World Health Organization Disability Assessment
Schedule II (WHODAS 2.0) score at outcome
assessment in the period day 91 ± 14 days after
randomisation. Type: continuous.
 Brain infarct size at imaging assessment in the
period 48 ± 24 hours after randomisation. Type:
continuous.
Safety outcomes
 Proportion of participants with at least one serious
adverse event (SAE) until outcome assessment in
the period day 91 ± 14 days after randomisation.
Type: binary.
 Number of SAEs per patient until outcome
assessment in the period day 91 ± 14 days after
randomisation. Type: rate.
Table 2 Power (based on an α = 0.05) of the secondary outcomes and serious adverse events provided inclusion of 800 patients
into the EuroHYP-1 trial
Outcome Proportion or mean
value in control
group
Standard deviation in the
control group for continuous
outcome
Minimal relevant intervention
effect - absolute risk reduction
relative to control group
Power
Score of NIHSS at 91 +/-14 days (sample size = 800) 8 pointsa 5 pointsa 2 pointsa 1.00
Serious adverse events at 91 +/-14 days
(sample size = 800)
20% NR 10% 0.98
Death or dependency, defined as modified Rankin
score > 2 at 91 +/-14 days (sample size = 800)
63% NR 7.25% 0.55
Brain infarct size at 48 +/-24 hours (sample size = 800) 10 mla 15 mla 2 mla 0.47
EQ-5D-5 L score at 91 +/-14 days (sample size = 800) 0.50 points 0.40 points 0.05 points 0.42
Death at 91 +/-14 days (sample size = 800) 17% NR 3.84% 0.33
NIHSS National Institutes of Health Stroke Score, EQ-5D-5 L EuroQoL quality-of-life scale, NR not relevant
aAssumed values
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Fig. 1 (See legend on next page.)
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Health economic outcome
 Incremental cost utility (cost per quality-adjusted life
years (QALY)) and incremental cost effectiveness
(cost per death or disability averted) ratios. Type:
continuous.
The analysis sets
The analysis populations for the statistical analyses
of this trial include the intention-to-treat population,
the per protocol set of patients, and the ‘learning
curve’ population.
The intention-to-treat population of patients
The intention-to-treat (ITT) population is defined as all
randomised patients classified according to the interven-
tion to which they were randomised (experimental and
control intervention groups) [2].
The per protocol set of patients
The per protocol set of patients is the subset of all rando-
mised patients without major protocol violations and classi-
fied according to the intervention to which they were
randomised. Major protocol deviations encompass: (1)
patients in the intervention group who do not reach a body
temperature of ≤ 35.0 °C within 3 hours after induction of
cooling; or (2) patients randomised in the intervention
group who do not achieve at least 6 hours of body
temperature at a level of ≤ 35.0 °C during the period from
beginning of hour 1 to the end of hour 12 of cooling.
According to this definition, the per protocol population
will be coded and defined in the data set before data lock,
so it cannot undergo changes subsequently.
The ‘learning curve’ population
The EuroHYP-1 trial is a very large and complex trial
with multiple nations and sites investigating a complex
intervention. To account for this, we define a ‘learning
curve’ analysis set, where we will analyse independently
the first five participants included at each centre and
compare those results to the results of all participants
minus the first five.
Statistical analyses
Analytical principles
Analyses will be conducted according to the intention-
to-treat principle [2] if not otherwise stated.
All primary tests of significance will be two-sided with
alpha = 5%. Analyses will be conducted blinded with the
two intervention groups coded as, e.g. 0 and 1. Two
conclusions will be drawn, one assuming 0 is the inter-
vention group and 1 is the control, and one assuming
(See figure on previous page.)
Fig. 1 Overview of patient schedule and data collection in the EuroHYP-1 trial (grey tone only for the experimental group). 1 Re-warming: hypothermia
group only. 2 Previous medication including alteplase. 3 Includes sodium, potassium, magnesium, creatinine, urea, gamma-glutamyl transpeptidase, ASAT,
ALAT, alkaline phosphatase, blood glucose; haemoglobin, haematocrit, erythrocytes, leukocytes, platelets, INR. Further samples may be taken throughout
the study at the discretion of the investigator. 4 Body temperature will be assessed according to local clinical practice with tympanic, bladder, or rectal
temperature measurement, except in patients randomised to therapeutic hypothermia from start of treatment phase (TP, beginning of hour 1) until end
of re-warming period, when bladder or rectal thermal probes will be used. During TP, body temperature will be assessed every 15 min during the first
3 hours (except at time points t = 0 min and t = 15 min) and every 60 min thereafter in patients randomised to therapeutic hypothermia, every 60 min
(except at time point t = 0 min) in patients randomised to best medical treatment alone, subsequently in all patients at 8-hour intervals until A6 (day 8 or
day of discharge from hospital, whichever occurs first). 5 The mRS assessment at outcome assessment (A7) will be recorded using a digital video camera.
The clip will then be transferred to the EuroHYP-1 outcome adjudication web portal. 6 Anti-shivering medication: induction: buspirone 10 mg p.o./
pethidine 50 mg i.v. (2 min); repeat doses of 10 mg buspirone p.o. may be administered as long as a maximum dose of 30 mg/24 h is respected; a
bolus of pethidine 25 mg i.v. may be given as long as an interval of at least 30 min is respected and a maximum dose of 500 mg/24 h is not exceeded.
24 h-doses include induction bolus. For the prevention and treatment of opioid-induced nausea and vomiting, a 5HT3RA may be administered as support
medication. 7 Induction of cooling: 20 ml/kg estimated bodyweight 4 °C isotone saline or Ringer´s lactate over a period of 30–60 min; EMCOOLS Brain.Pad,
if available. 8 IMDs permitted for cooling: EMCOOLS Brain.Pad (for induction of cooling only); Medivance/Bard Arctic Sun temperature management system
with heat exchange control unit Arctic Sun 2000 or Arctic Sun 5000 and ArcticGel Pads; MTRE CritiCool temperature management system with
heat exchange control unit CritiCool, accessoires and CureWrap; Zoll IVTM system with heat exchange control unit CoolGard 3000 or Thermogard XP,
CoolGard start-up kit and intravascular temperature management catheters ICYy 3893 AE or ICY 3893 CO. 9 If endovascular cooling is performed, the
catheter insertion site must be visually inspected for detection of bleeding/haematoma in 3-hour intervals during TP and once 3 hours after removal
of the intravascular catheter. 10 Monitoring for pneumonia includes monitoring of oxygen saturation and body temperature, physical examination
(auscultation, percussion) and, if clinically indicated, chest X-ray. Monitoring for signs of pneumonia must be performed from screening assessment
(A1, within 90 minutes before the start of the treatment phase TP) until A6 (day 8 or day of discharge from hospital, whichever occurs first). 11 Patient
location during stay in hospital must be assessed at 12:00 hours on each day in hospital. 12 WHODAS 2.0 questionnaire and EQ-5D questionnaire must
be filled in by the patient or his/her relative/carer at outcome assessment (A7). 13 Health Recovery Guide and Diary: Section 6: filled in by the patient
every day from discharge to V7; Section 7: filled in by the carer/relative prior to V7. 14 For participation in the biomarker sub-study a special informed
consent form must be filled in by the patient or his/her legal representative. Assessment at End of Hour 24 ± 2 hours. 15 Only selected study sites. 16
Informed consent will be obtained in accordance with national regulatory requirements. 17 NIHSS assessment at End of Hour 24 ± 2 hours. 18 Starting
at t = 30 min. 19 Every 60 minutes only. 20 Prior to intended repeat administration of pethidine. CT computed tomography, ECG electrocardiogram,
EQ-5D-5 L EuroQoL quality-of-life scale, GCS Glasgow coma scale, MRI magnetic resonance imaging, NIHSS National Institutes of Health Stroke Score,
SAE serious adverse event, WHODAS World Health Organization Disability Assessment Schedule
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the opposite. After two abstracts with two conclusions
have been written and both accepted by the Steering
Group, the code will be broken.
The primary analyses of primary, secondary, and
exploratory outcomes will be those of the intention-to-
treat population adjusted for the protocol-specified
stratification variable and the minimisation variables,
and if necessary using data sets generated using multiple
imputation.
Missing values of the primary outcome
By definition, none of the adjusting variables will have
missing values (otherwise the stratification and mini-
misation could not have been conducted). So only the
outcome value may be missing. Furthermore, we assume
there are no useable auxiliary variable, i.e. no other variable
that has a moderate to high correlation with the outcome
(|r| > 0.40) and yet is not intended to be a predictor in the
regression model. In this situation, the problem is easily
solved. If we are willing to assume that the data are miss-
ing at random, the maximum likelihood analysis reduces
to a complete case analysis [3, 4]. Consequently, we simply
delete participants that are missing on the outcome and
estimate the regression with the remaining participants.
However, if useable auxiliary variables have been identified,
a multiple monotone imputation will be conducted, which
will include the primary outcome and the covariates of the
analytical model plus the auxiliary variables. As a sensitiv-
ity analysis to assess the potential impact of outcome
values missing not at random (MNAR), we will conduct a
worst/best case scenario imputation, i.e. a single value im-
putation of the missing values. The imputations use a
minimum value or a maximum value (0 respectively 5 of
the modified Rankin scale in that we assume that a patient
who died will not have the mRS value missing). Missing
values are imputed by the minimum value in one inter-
vention group, and in the other intervention group by
the maximum value and vice versa. Once the random-
isation code is broken the results of the two compari-
sons may be interpreted.
Power of the original secondary outcomes
As the sample size is based on the primary outcome, we
have calculated the power of each of the originally
planned secondary outcomes given the sample size of
800 patients.
Death day 91 ± 14 days after randomisation: the implied
clinically relevant minimal change in mortality that needs
to be detected may be calculated based on (1) the mortality
of 17% found in the meta-analysis quoted in the protocol
[1]; (2) the assumption that wherever the mRS is dichoto-
mised, the odds ratio for treatment versus control will be
the same, the ‘common odds ratio’; and (3) the require-
ment that this common odds ratio should not be larger
Fig. 2 Flow of participants in the EuroHYP-1 trial
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than 0.74 (see the sample size calculation). Let the
unknown change in mortality in the experimental group
be x. If we assume the OR for the dichotomy mRS > 5
compared to mRS ≤ 5 will be 0.74 and the mortality of the
control group is 17% as quoted in the meta-analysis, we
may find x by solving the equation OR = ((0.17–x)/(0.83 +
x))/(0.17/0.83) = 0.74 to obtain x = 0.0384 giving a mortal-
ity of 0.1700 – 0.0384 = 0.1316 in the cooled patients
versus 0.1700 in the controls. Using a sample size of 800
participants, the power is found to be 0.33.
Death or dependency (mRS > 2) 91 ± 14 days after
randomisation: using the same reasoning, the power of
this outcome can be calculated by solving the equation
(0.63–x)/(0.37 + x))/0.63/0.37 = (0.63 – x)0.63/(0.37 +
x)0.37 = 0.74 as 63% of the patients in the meta-analysis
had mRS > 2 implying x = 0.0725. The power may then
be calculated to be 0.55.
NIHSS score 91 ± 14 days after randomisation: assum-
ing a minimal relevant difference of 2 points, a standard
deviation (SD) of 5 points [5], an α of 0.05, and a sample
size of 800 participants, the power may then be calcu-
lated to 1.00.
EQ-5D-5 L score 91 ± 14 days after randomisation:
assuming a minimal relevant difference of 0.05 points, a
SD of 0.40 points [6–9], an α of 0.05, and a sample size of
800 participants, the power may then be calculated to 0.42.
WHODAS 2.0 score 91 ± 14 days after randomisation:
we originally planned to analyse the World Health
Organization Disability Assessment Schedule II (WHO-
DAS 2.0) score at outcome assessment in the period day
91 ± 14 days after randomisation. However, due to diffi-
culties in assessing the clinical meaning, we are not able
to calculate the power, and we will thus analyse this as
an exploratory outcome.
Brain infarct size 48 ± 24 hours after randomisation:
assuming a minimal relevant difference of 2 ml, a SD of
15 ml [10], an α of 0.05, and a sample size of 250 partici-
pants, the power may then be calculated to 0.18.
Accordingly, this outcome will be exploratory.
Number of patients with at least one serious adverse
events 91 ± 14 days after randomisation: assuming a
control group event proportion of 20% of patients with
at least one SAE, an intervention group event proportion
of 10% [11], an α of 0.05, and a sample size of 800
participants, the power may then be calculated to 0.98.
Mean number of SAEs per patients: As we do not have
prior data to indicate a probable minimal relevant differ-
ence, we cannot calculate power for this outcome. These
data will be analysed as an exploratory outcome.
The results of calculations of the power are all shown
in Table 2. These results are used to determine the
sequence in which the secondary outcomes should be
tested using the fixed-sequence approach, i.e. the
sequence will be as follows:
1. Score on NIHSS at outcome assessment in the
period day 91 ± 14 days after randomisation.
2. Proportion of participants with at least one serious
adverse event (SAE) until outcome assessment in the
period day 91 ± 14 days after randomisation.
3. Death or dependency, defined as a score on the
mRS > 2 at outcome assessment in the period day
91 ± 14 days after randomisation.
4. Brain infarct size at imaging assessment in the
period 48 ± 24 hours after randomisation.
5. EQ-5D-5 L score at outcome assessment in the
period day 91 ± 14 days after randomisation.
6. Death at outcome assessment in the period day 91 ±
14 days after randomisation.
The exploratory outcomes are:
1. WHODAS 2.0 score at outcome assessment in the
period day 91 ± 14 days after randomisation.
2. Number of SAEs per patient until outcome
assessment in the period day 91 ± 14 days after
randomisation.
Presentation of results in tables
Tables 3, 4, 5 and 6 show how the results of the analysis
of the primary outcome (Table 3), the binary secondary
outcomes (Table 4), the continuous secondary outcome
and exploratory outcomes (Table 5), and the SAE data
(Table 6) will be presented.
Table 3 Comparison of the distributions of the modified Rankin scale (mRS) between the two intervention groups in each analysis set
(intention-to-treat or per protocol)
Population studied Intervention
group
mRS = 0 mRS = 1 mRS = 2 mRS = 3 mRS = 4 mRS = 5 mRS = 6 Common OR P of difference
N (%) N (%) N (%) N (%) N (%) N (%) N (%) (95% CI) (reference = group 0)
Intention-to-treat (ITT) Group 0
Group 1
Per protocol (PP) Group 0
Group 1
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Multiplicity
We cannot claim a significant beneficial effect of the inter-
vention in the trial if the primary outcome is neutral and a
secondary outcome is statistically significant. Therefore,
any testing addressing the multiplicity problem must not
reduce the power of the test of the primary outcome as
compared to the situation where we declare the secondary
outcomes exploratory and only test the primary outcome
using α = 0.05. Consequently, the primary outcome must
be tested initially and using α = 0.05. These requirements
may be fulfilled if we use a pre-specified testing sequence
(fixed-sequence procedure) where each outcome is tested
at α = 0.05 [12]. However, as soon as a non-significant re-
sult is obtained, the testing is stopped. However, for ex-
ploratory purposes we will calculate the P values of the
remaining tests and present them. We will use the fixed-
sequence procedure starting with the primary outcome
and followed by the secondary outcomes, and the explora-
tory outcomes ordered according to descending power
(see Table 2).
Subgroup analysis
The duration of the cooling intervention was reduced
from 24 hours to 12 hours after the recruitment of 50 par-
ticipants. To investigate this protocol change, we will con-
duct a subgroup analysis for the primary and secondary
outcomes. In the analysis, we will compare the partici-
pants who were included before the protocol change to
participants included after the protocol change.
Sensitivity analyses
The analyses of the primary and secondary outcomes
will be repeated using the per protocol population and
the ‘learning curve’ population.
Table 4 Comparison of the distributions of the secondary binary outcomes between the two intervention groups in each analysis
set (intention-to-treat and per protocol)
Population Intervention
group
Outcomes
Death mRS > 2
N (%) Relative risk (RR) (95% CI) P N (%) RR (95% CI) P
Intention-to-treat (ITT) Group 0
Group 1
Per protocol (PP) Group 0
Group 1
mRS modified Rankin score, CI confidence interval
Table 5 Comparison of distributions of the secondary continuous outcomes between the two intervention groups in each analysis
set (intention-to-treat or per protocol)
Outcome Population Intervention
group
Percentiles N Mean
(SD)
(Minimum,
maximum)
P of
difference25% 50% 75%
NIHSS score Range of possible scores at 91+/-14 days
(RS): 0 to 42 Worst = 42
Intention-to-treat (ITT) Group 0
Group 1
Per protocol (PP) Group 0
Group 1
EQ-5D-5 L score at 91+/-14 days RS: 0 to 100 Worst = 0 ITT Group 0
Group 1
PP Group 0
Group 1
Brain infarct size at 48 +/-24 hours Worst = 1 ITT Group 0
Group 1
PP Group 0
Group 1
WHODAS 2.0 score at 91+/-14 days ITT Group 0
Group 1
PP Group 0
Group 1
SD standard deviation, NIHSS National Institutes of Health Stroke Score, EQ-5D-5 L EuroQoL quality-of-life scale
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Analysis of the primary and the secondary outcome
The primary outcome
The primary efficacy variable, the score on the mRS at
the outcome assessment (day 91 ± 14 days), will be
determined with ordinal (with more than two categories)
logistic regression. The assumption about proportional
odds will be accepted if the difference between the
frequency in group 1 and that of group 2 in the various
categories are all positive and different from 0 or are all
negative and different from 0. If the assumption of the
ordinal regression analysis model is not fulfilled, the
groups will be compared using a non-parametric method
(van Elteren and stratification by nationality of centre)
and the result will be the primary result. If the assump-
tion of the model is fulfilled, the result of the adjusted
analysis will be the primary result.
The secondary and the exploratory outcomes
Frequencies and percentages per group as well as risk ra-
tios with 95% confidence interval (CI) will be reported for
binary outcomes. Continuous variables and rate variables
will be summarised using mean, standard deviation, 25, 50
and 75 percentiles, and minimum and maximum values.
Logistic regression for binary quantities, the general lin-
ear univariate model for continuous outcomes, and the
Poisson distribution or negative binomial distribution for
rate outcomes will be used. If the assumptions of the Pois-
son or negative binomial models are not fulfilled with
reasonable approximation, a non-parametric method (van
Elteren adjusted by nationality of centre) will be used.
Outline of exploratory analysis of the temperature variables
and time to death
Assuming that the temperature is measured at the same
times relative to the time of the start of intervention, a
mixed model may be used to characterise the time
course of those patients who do not die during the treat-
ment. The model is given by temperature = INT time
time*INT, where INT is the intervention indicator. Add-
itionally, the time to death from start of treatment with
censoring at end of treatment and at 91 days +/-14 days
including baseline variables measured at or prior to start
of treatment may be analysed using a Cox proportional
hazards model. The mean values of all the actual
measured temperatures in the intervention group will be
displayed in a graph with mean +/- 2 standard errors.
Health economic evaluation
The economic assessments will be conducted in align-
ment with the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement [13]. The
prospective analysis will determine the cost per QALY
gained with systemic cooling compared with standard
care over a 3-month period. Acute hospital post-
discharge resources will be considered in the evaluation.
Procedural costs for systemic cooling will be obtained
with a bottom-up micro-costing approach in order to
Table 6 Amendments made relative to the original statistical analysis plan published in the protocol
Topic described in original
statistical analysis plan
Handling of topic in the present
amended statistical analysis plan
Reason for action
No adjustment for nationality. Adjustment for nationality To improve the power by preventing upward
bias of the standard error of the outcome.
Power calculation of secondary
outcomes is missing
Calculation of power conditional on
sample size
To be used when defining the test ordering of
the secondary outcomes
Difficulties involved in interpreting an
effect on a secondary outcome that
can only be measured in surviving
patients was not addressed
The worst possible score is assigned
to the dead patients
A surplus of patients in one group relative to the
other group may die before the outcome is
measured. In the other group the corresponding
surviving patients may (or may not) have very
poor outcomes
No multiplicity adjustment The fixed-sequence testing procedure
will be applied with the primary outcome
to be tested first and followed by the
secondary outcomes ordered according
to falling power
To keep the family-wise error rate≤ 0.05
A search for auxiliary variables and if found
followed by imputation of the primary
outcome was not considered
Missing value handling procedure
revised accordingly
To improve the efficiency of a multiple imputation
of missing values of the primary outcome
The analytic potential of the exploratory
temperature data was not expanded on
An outline of an exploratory mixed model
analyses of the temperature data and Cox
analyses of time to death with censoring
at end of treatment and at 91 days +/-
14 days is now included
To assess if the temperature has an impact on
short-term and long-term mortality and supple
ment the result of the analysis of the second
secondary outcome
Sample size of 1500 participants Sample size reduced to 800 participants Due to exceptionally slow enrolment, we realised
that this target was no longer realistic
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identify all relevant cost components of the procedure
and value each component for all individual patients,
using procedure duration, staff, and number of medical
devices as variables. All-cause hospital admissions within
3 months of the first treatment will also be included in
cost computations. Non-hospital resources are not con-
sidered in view of the short follow-up duration.
Cost of systemic cooling will be the manufacturer’s
price, and staff costs will be estimated from gross salar-
ies. Hospital inpatient costs will be estimated using
current average national cost of each patient’s diagnosis-
related group (DRG), adjusted for actual length of stay,
and resources consumed during hospitalisation. Hospital
re-admissions will be based on tariffs. All costs will be in
Euros (€) and are not discounted. Health-related quality
of life collected using the EQ-5D-5 L self-administered
questionnaire at baseline and 3 months will be used to
elicit utility values based on country-specific tariffs. The
difference in QALYs will be estimated as the difference
in the area between the utility curves for the two groups.
We will undertake a fully pooled analysis for clinical
outcomes and a country-specific analysis for costs (based
on the countries with the highest patient volume) [14].
The cost-utility analysis will estimate incremental costs
per QALY and the cost-effectiveness incremental cost per
death or disability (as defined in the secondary outcomes)
averted. Between-group comparisons of QALYs and costs
will be performed with the statistical test appropriate for
their distribution, with a significance threshold of 0.05. A
joint comparison of costs and effects will be performed by
nonparametric bootstrapping with 1000 resamples and
the result of the bootstrap replications presented on the
cost-effectiveness plane (scatterplot).
Overview of changes to the original statistical analysis
plan for the primary and the secondary outcomes
Table 7 presents an overview of the changes relative to the
original statistical analysis plan and explain the reasoning
behind. The only substantial changes relative to the
original plan includes that we now: (1) adjust the analyses
by the protocol-specified stratification variable, i.e. nation-
ality to improve the power [15]; (2) power calculations for
secondary outcomes; (3) address the multiplicity problem
by using a fixed-sequence procedure starting with the
primary outcome followed by the secondary outcomes
ordered according to falling power; (4) due to the low
power involved in detecting small (1–5%) differences in
mortality between the groups, assign worst possible score
to patients who are not alive at the planned date of meas-
urement of the continuous scores; (5) include auxiliary var-
iables in the potential multiple imputation of missing value
of the primary outcome to improve the efficiency of the
imputation; and (6) outline a supplementary exploratory
analysis of the temperature measurements and time to
death; (7) substantial reduction of sample size.
Discussion
With this updated detailed statistical analysis plan we
present the different analyses in the main publication of
the EuroHYP-1 trial to avoid risks of outcome reporting
bias and data driven results [16, 17]. Of the pre-specified
outcomes in the trial, we choose to report only the pri-
mary outcome, the secondary outcome, two exploratory
outcomes including serious adverse events in the main
publication because of the complexity of the remaining
safety variables and the detailed economical quantities
that require separate publications.
The interpretation of the effect on outcomes which may
only be measured in surviving patients
Formally, three of the original secondary outcomes
(NIHSS, EQ-5D-5 L, and infarct size) are only measurable
in patients who survive until these outcomes were planned
to be measured. This may make the interpretation of a
significant effect on each of the last four secondary out-
comes somewhat difficult when the power of detecting a
small difference between the mortalities in the two groups
is low. A surplus of patients in one intervention group
relative to the other group may die before the outcome is
Table 7 Total number of serious adverse events (SAEs), and number of patients with at least one SAE groups in each analysis set
(intention-to-treat or per protocol)
Types of
events
Group 0 Group 1
Events, N Patients with at least one event, N Patients assessed, N Events, N Patients with at least one event, N Patients assessed, N
Any event
Event type
1
Event type
2
Event type
3
Etc
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measured. In the other intervention group, the corre-
sponding surviving patients may (or may not) have very
poor outcome values which may make the first group look
good if the mortalities do not differ significantly.
Given the sample size of 800 patients and assuming the
mortality in one group is 0.17 (e.g. in the control group,
see above) the probability of not detecting an absolute
reduction in mortality in the experimental group of 0.01,
0.02, 0.03, 0.04, and 0.05 is 0.93, 0.89, 0.81, 0.70, and 0.57,
respectively. Thus, differences in mortality of the interven-
tion groups of 5% or less are likely to remain undetected
with a relatively high probability. Therefore, we have
elected to include the dead patients in the comparison
between the two intervention groups by assigning the
worst possible score to the dead patients. The EQ5D5L is
used to estimate QALYs gained in each arm of the trial
population. QALYs are estimated by summing up the time
spent in each state multiplied by the quality of life attrib-
uted to this state. By definition, the value of QALYs is zero
from the time of death onwards. Total QALYs will be
computed and reported for each patient for the entire
duration of the follow-up.
For the study of prognostic markers in the EuroHYP-1
trial, we will apply similar principles as in the Clarithro-
mycin in Patients with Stable Coronary Heart Disease
trial (CLARICOR) trial [18]. The study of prognostic
markers will not be part of the primary publication.
In conclusion, major adjustments compared with the
original statistical analysis plan encompass: (1) adjustment
of analyses by nationality; (2) power calculations for the
secondary outcomes; (3) use of a fixed-sequence testing
procedure starting with the primary outcome followed by
the secondary outcomes ordered according to falling
power to address the multiplicity problem; (4) assignment
of worst possible score to patients who are not alive at the
planned date of measurement of the continuous scores; (5)
improved imputations; (6) outline of a supplementary
exploratory analysis of the temperature measurements and
time to death; and (7) substantial reduction of sample size.
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